Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRAX-562 Phase 2 trial in pediatric SCN2A/SCN8A developmental and epileptic encephalopathies
2022-502298-41-00Phase 2Authorised
- Sponsor
- Praxis Precision Medicines
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of relutrigine in SCN2A developmental and epileptic encephalopathy (SCN2A-DEE) and developmental and epileptic encephalopathy 13 (DEE13) (3 arms), sponsored by Praxis Precision Medicines. Planned start Aug 2023; status: authorised.
02
Drugs
relutrigine
03
Conditions
SCN2A developmental and epileptic encephalopathy (SCN2A-DEE)developmental and epileptic encephalopathy 13 (DEE13)
Beyond the preview
Go deeper on 2022-502298-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502298-41-00.